Sofinnova Partners SAS's Form 4 filing
CinCor Pharma, Inc. (CINC) · filed Jan 13, 2022
- Accession no.
- 0001209191-22-003195
- Filed
- Jan 13, 2022, 4:36 PM ET
- Trade date
- Jan 11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $3.52M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sofinnova Partners SASCIK 0001574139 | 10% Owner |
| Sofinnova Capital IXCIK 0001849915 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common Stock | CConversionAcquired | +3,867,646 | –F1 | – | 3,867,646 | Indirect | |
| Jan 11, 2022 | Common Stock | PPurchaseAcquired | +220,000 | $16.00 | +$3,520,000 | 4,087,646 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common Stock | CConversionDisposed | −2,941,176 | $0.00 | $0 | 0 | Indirect | |
| Jan 11, 2022 | Common Stock | CConversionDisposed | −926,470 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
Referenced by the price of 1 transaction in Table I.